| __timestamp | MiMedx Group, Inc. | Vertex Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 90480000 | 305409000 |
| Thursday, January 1, 2015 | 133384000 | 377080000 |
| Friday, January 1, 2016 | 179997000 | 432829000 |
| Sunday, January 1, 2017 | 220119000 | 496079000 |
| Monday, January 1, 2018 | 258528000 | 557616000 |
| Tuesday, January 1, 2019 | 198205000 | 658498000 |
| Wednesday, January 1, 2020 | 181022000 | 770456000 |
| Friday, January 1, 2021 | 198359000 | 840100000 |
| Saturday, January 1, 2022 | 208789000 | 944700000 |
| Sunday, January 1, 2023 | 211124000 | 1136600000 |
| Monday, January 1, 2024 | 1464300000 |
Infusing magic into the data realm
In the ever-evolving landscape of the pharmaceutical industry, understanding financial trends is crucial. Over the past decade, Vertex Pharmaceuticals Incorporated and MiMedx Group, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Vertex Pharmaceuticals has seen a staggering 272% increase in SG&A expenses, reflecting its aggressive growth and expansion strategies. In contrast, MiMedx Group's SG&A expenses have grown by approximately 133%, indicating a more conservative approach.
Vertex's expenses surged from around $305 million in 2014 to over $1.1 billion in 2023, highlighting its commitment to innovation and market penetration. Meanwhile, MiMedx's expenses rose from about $90 million to $211 million, suggesting a focus on steady growth. These trends underscore the differing strategies of these companies in navigating the competitive pharmaceutical landscape.
Selling, General, and Administrative Costs: Novo Nordisk A/S vs MiMedx Group, Inc.
Selling, General, and Administrative Costs: AstraZeneca PLC vs Vertex Pharmaceuticals Incorporated
SG&A Efficiency Analysis: Comparing Sanofi and MiMedx Group, Inc.
Bristol-Myers Squibb Company or Vertex Pharmaceuticals Incorporated: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Vertex Pharmaceuticals Incorporated or Exelixis, Inc.
Vertex Pharmaceuticals Incorporated or Arrowhead Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Vertex Pharmaceuticals Incorporated vs Viridian Therapeutics, Inc.
Incyte Corporation and MiMedx Group, Inc.: SG&A Spending Patterns Compared
Jazz Pharmaceuticals plc vs MiMedx Group, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Halozyme Therapeutics, Inc. vs MiMedx Group, Inc.
Comparing SG&A Expenses: Alkermes plc vs MiMedx Group, Inc. Trends and Insights
Comparing SG&A Expenses: Verona Pharma plc vs MiMedx Group, Inc. Trends and Insights